Answers are grounded in this paper and cite their sources.
Retrospective study uncovers recombinant peanut allergen cut-offs for predicting anaphylaxis in sensitized children, highlighting the strong diagnostic utility of Ara h 2.
AIM: Component-resolved diagnostics (CRD) improve diagnosis and risk stratification in peanut allergy. We evaluated the diagnostic performance of five recombinant peanut allergens for predicting peanut-induced anaphylaxis. METHODS: We retrospectively analysed 164 children with peanut sensitization and elevated IgE to recombinant allergens. Patients were classified as Group A (no/mild symptoms) or Group B (anaphylaxis). Specific IgE levels were compared, ROC curves identified optimal cut-offs, and odds ratios were estimated using Firth penalized logistic regression. RESULTS: Ara h 1-, Ara h 2- and Ara h 3-specific IgE levels were significantly higher in Group B. The strongest association was observed for Ara h 2 (OR 19.65, 95% CI 5.83-72.56; p < 0.001), followed by Ara h 3 (OR 7.27, 95% CI 2.31-26.34; p = 0.001) and Ara h 1 (OR 6.21, 95% CI 1.77-20.73; p = 0.006). Ara h 8 was not associated with anaphylaxis, whereas Ara h 9 showed an inverse association (OR 0.23, 95% CI 0.06-0.73; p = 0.012). Optimal cut-offs were Ara h 1 ≥ 2.60, Ara h 2 ≥ 10.36 and Ara h 3 ≥ 0.18 kUA/L. CONCLUSIONS: Specific IgE to Ara h 1, Ara h 2 and Ara h 3, particularly Ara h 2, was associated with peanut-induced anaphylaxis. The proposed cut-offs require prospective validation.
No takes yet. Share an insight, caveat, or question.
Gazzolari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: